Mikhail Blagosklonny Develops TOR Signaling to Fight Age-Related Diseases

For decades, cancer has been one of the leading causes of death globally. What was once the worry of just the affected has now become the primary concern of most donors, physicians, and scientists across the world. One such scientist is Mikhail Blagosklonny, a professor of oncology. He has made a significant impact and majorly contributed to the fight against cancer. Mikhail specializes in cancer biology as well as treatment therapies. Having strong academic credentials and research background, he has for years, worked on developing therapies focused on finding the treatment for cancer and age-related diseases through revolutionary methodologies. Follow Mikhail on Google Scholar

Contribution

Mikhail is a renowned oncologist who focuses on research-based findings for cancer treatment. He has authored several articles on cancer treatment and therapies. He also has co – authored several chapters of books regarding cancer and various therapies involved in finding treatment. His reviews offer information on molecular as well as cellular biology. He studies cancer cells and their existence in the human body as well as how to kill the active cancer cells by allowing the active, healthy body cells to survive. His vastly cited works concentrate on the molecular aging theory.

TOR Signaling

Towards this end, Mikhail Blagosklonny proposed TOR signaling. He explains that the rapamycin prolongs life by preventing apoptosis and delaying autophagy. This, in turn, promotes cellular protein synthesis. He further explains that these processes are essential in slowing down aging. As a result, there is a slowdown in the commencement of age-related disease. According to Blagosklonny, the over –expression of rapamycin prevents autophagy. This leads to the development of tumors. The result works well in cancer treatment. Blagosklonny believes that a clear understanding of the processes involved in TOR signaling aid in the development of cancer treatment therapies, drugs, and anti-aging treatment.

Blagosklonny’s Profile

Mikhail is a professor of oncology at the Roswell Park Institute of Cancer Research. He attended the First Pavlov State University. He majored in internal as well as external experimental medicine. He is the editor of Oncotarget, a peer-review medicine journal that aims to disseminate clinical information on diseases and treatment. Blagosklonny commits to developing revolutionary methods of cancer treatment and age related diseases through research. Visit classroomvoices.org to read more about Mikhail.